Reprogenix Bioscience
- Biotech or pharma, therapeutic R&D
Reprogenix’s lead candidate, RGB-5088, is lab-grown islets clinically validated to provide a functional cure for type 1 diabetes. Findings from its pilot clinical study were published in Cell [DOI: 10.1016/j.cell.2024.09.004], demonstrating for the first-time rapid and complete reversal of diabetes after transplantation of induced pluripotent stem cell-derived islets for type 1 diabetes therapy, as well as an excellent safety profile. These findings were replicated in all 3 patients of the pilot study, with insulin independence achieved within 75 days in all cases. Clinical trials have commenced, with biologics license application projected for 2027.
Reprogenix is co-founded and led by Dr. Hongkui Deng – world-renowned pioneer in regenerative medicine and non-genetic cellular reprogramming technologies for which he was awarded the 2024 Future Science Prize, Dr. Lieming Ding, chairman of Betta Pharmaceuticals and innovator of oncology therapies, and biotech entrepeneur Ms. Casey Lou.
Address
HangzhouChina
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}